Clinical Trials for Jeffrey Sosman

8 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
Basic ScienceVICCMEL09109
06/03/2010
Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy
TreatmentVICCMELP1388
03/24/2014
A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.
TreatmentVICCMEL1351
10/17/2013
A Phase 2 study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
TreatmentVICCMELP1325
09/25/2013
A Phase IB/II, Multicenter, Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF mutant melanoma
TreatmentVICCPHI1328
09/05/2013
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination with Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma
TreatmentVICCMEL1256
12/06/2012
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence
TreatmentVICCPHI1231
11/19/2012
Phase 1/2 Study of PI-3K Inhibition with PX-866 Combined with Vemurafenib (BRAF Inhibitor) in Patients with BRAF-Mutant Cancer Including Advanced Melanoma
TreatmentVICCMEL0759
08/01/2008
A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma

Back to Find By Doctor

You do not have JavaScript enabled. This site works better with JavaScript turned on.